<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03270371</url>
  </required_header>
  <id_info>
    <org_study_id>MCO-CS-559/16S</org_study_id>
    <nct_id>NCT03270371</nct_id>
  </id_info>
  <brief_title>Modulation of Inflammation by Medium Cut Off Membranes</brief_title>
  <acronym>MCO-IF</acronym>
  <official_title>Medium-term Modulation of the Inflammatory Profile by Medium-cut Off Membranes in Patients With End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines whether medium-cut off dialysis results in improved blood purification of
      large middle molecules e.g. inflammatory molecules compared to hemodialysis (HD) treatments
      with conventional high-flux dialyzers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular events and sepsis remain the leading causes of mortality in patients on
      maintenance hemodialysis. Thus expectancy of life for these patients is comparable to the
      prognosis of metastasized cancer. So far the exact mechanisms causing excess mortality in
      hemodialysis patients remain elusive, but chronic inflammation seems to play a central role
      in the pathogenesis of cardiovascular disease in HD patients.

      Keeping this in mind the Theranova medium-cut off membrane, with its ability to clear middle
      molecules (0,5-50 kDa), seems suitable to further improve clearance of inflammatory mediators
      as the non-protein bound inflammatory mediators lie within the cut off range of this
      membrane. The investigators designed this study to get information on the changes in the
      inflammatory milieu in dialysis patients when using medium-cut off membranes which are know
      to significantly reduce cytokines compared to standard high-flux dialyzers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Medium cut off Dialyzer compared with standard of care High-Flux Dialyzer (Fx Cor Diax 60®). No others changes in our standard of care maintenance dialysis is planned, dialysis specific parameters such as blood flow will be kept unchanged during the study period).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>no masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammation</measure>
    <time_frame>240 days (cross-over design, multiple measurements)</time_frame>
    <description>change of inflammatory score (inflammatory score is derived from multiple biomarkers)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in calcification status</measure>
    <time_frame>240 days (cross-over design, multiple measurements)</time_frame>
    <description>calcification score derived from several pro- and anticalcifying biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in calcification propensity</measure>
    <time_frame>240 days (cross-over design, multiple measurements)</time_frame>
    <description>this values measures the resistence of serum to a calcification stimulus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>MCO Dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Theranova Dialyzer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard High Flux Dialysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard High Flux Dialyzer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medium cut off dialysis</intervention_name>
    <description>Hemodialysis</description>
    <arm_group_label>MCO Dialysis</arm_group_label>
    <other_name>Theranova Dialyzer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard High Flux Dialyzer</intervention_name>
    <description>Hemodialysis</description>
    <arm_group_label>Standard High Flux Dialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  time since initiation of dialysis &gt; 3 months

          -  age &gt; 18 years

        Exclusion Criteria:

          -  time since initiation of dialysis &lt; 3 months

          -  age &lt; 18 years

          -  ongoing acute or chronic infection/malignoma, because this will interfere with
             inflammatory baseline values

          -  major surgery less than 2 weeks before inclusion in the study

          -  pregnancy

          -  mental illness

          -  lack of written and informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Schmaderer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>attending Department of Nephrology, Klinikum rechts der Isar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Schmaderer, MD</last_name>
    <phone>0049894140</phone>
    <phone_ext>5053</phone_ext>
    <email>christoph.schmaderer@mri.tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georg Lorenz, MD</last_name>
    <phone>0049894140</phone>
    <phone_ext>6704</phone_ext>
    <email>georg.lorenz@mri.tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of nephrology, Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Schmaderer, M.D.</last_name>
      <phone>0049-89-4140</phone>
      <phone_ext>6701</phone_ext>
      <email>christoph.schmaderer@lrz.tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Georg Lorenz, M.D.</last_name>
      <phone>0049-89-4140</phone>
      <phone_ext>6704</phone_ext>
      <email>georg.lorenz@googlemail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christoph Schmaderer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ronco C, La Manna G. Expanded Hemodialysis: A New Therapy for a New Class of Membranes. Contrib Nephrol. 2017;190:124-133. doi: 10.1159/000468959. Epub 2017 May 23. Review.</citation>
    <PMID>28535525</PMID>
  </reference>
  <reference>
    <citation>Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, Hulko M, Boehler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Fiedler R, Girndt M. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial. PLoS One. 2017 Jan 13;12(1):e0169024. doi: 10.1371/journal.pone.0169024. eCollection 2017.</citation>
    <PMID>28085888</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

